Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Improving Treatment Outcomes of Patients With Waldenstrom Macroglobulinemia

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal IgM. With an estimated 1,500 new cases reported in the United States annually, the malignancy accounts for 2% of non-Hodgkin lymphomas. Unfortunately, WM is considered incurable with available therapies. Patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, whereas those with high-risk disease have a 5-year survival rate of only 36%.

TARGET AUDIENCE

Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with WM

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Assess factors to risk stratify patients with WM
2. Differentiate emerging efficacy and safety data on novel therapeutic approaches for treatment-naive and relapsed/refractory WM
3. Apply strategies to monitor and manage adverse events associated with novel therapies for WM

Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.

Expiration

May 09, 2020

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Monograph, Online

Credits / Hours

1.0

Accreditation

ACCME, ANCC

Presenters / Authors / Faculty

Morie A. Gertz, MD, MACP (Chairperson)
Professor of Medicine
Rochester Mayo Clinic

Toni Dubeau, RN, NP
Nurse Practitioner
Bing Center for Waldenström's Macroglobulinemia

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Pharmacyclics.

Keywords / Search Terms

i3 Health i3 Health, WM, Waldenstrom macroglobulinemia, Waldenstrom, hematologic malignancies, hematology, oncology, CME, CE, free CME, free CE, oncology CME, oncology CME Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.